Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Two different responsive organosilica nanocarriers to combine chemo- and immunotherapy against cancer

  • Sancho‐Albero, María
  • Lucrezia Fenaroli, Alessia
  • Scaccaglia, Mirco
  • Matteo, Cristina
  • Grasselli, Chiara
  • Zucchetti, Massimo
  • Frapolli, Roberta
  • Nastasi, Claudia
  • De Cola, Luisa
The combination of chemo- and immunotherapy was recently demonstrated to improve a patient's response to therapy, giving rise to an emerging cancer treatment known as chemoimmunotherapy (CIT). Despite the promising benefits of CIT, the most important challenges are (i) the simultaneous or time-controlled delivery of two drugs and (ii) the selective uptake into different cells for each of the drugs: cancer cells for the chemotherapeutic and macrophages for the immunostimulation actives. Herein, a delivery strategy based on morphologically different stimuli-responsive breakable organosilica nanocarriers is exploited to transport two distinct drugs in the different cells using different times of delivery. We employ stimulus-sensitive, PEGylated organosilica nanocages to encapsulate the chemotherapeutic agent doxorubicin, which is preferentially taken up by tumor cells vs macrophages. On the other hand, similar size mesoporous organosilica nanoparticles, preferentially internalized by macrophages, are filled with the immunostimulator resiquimod. The administration in a sequential manner of the two different nanocarriers allowed us to assess the integrated effect of the combined therapy versus treatment with a single drug. In vitro work clearly shows an important reduction of tumor cell viability when both chemo- and immunotherapeutic agents are delivered., This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement (FET-Open No 964386), project acronym “MimicKEY”. M. S.-A. thanks the AIRC-Foundation for a Postdoctoral fellowship in Italy (26907-2021) and the AECC for postdoctoral research fellowship funding (POSTD234966SANC), “Ayuda a Talento AECC 2023”. C.N. is supported by Fondazione Beppe e Nuccy Angiolini Onlus., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutathione threshold-triggered selective breakability of organosilica nanocapsules

  • Mosseri, Andrea
  • Rueda-Flores, Ana
  • Hueso, José L.
  • Urriolabeitia, Esteban P.
  • De Cola, Luisa
  • Santamaría, Jesús
The data that support the findings of this study are available from the corresponding author upon reasonable request., This article also appears in: Catalytic Strategies for Therapy and Diagnosis. Society Volumes: Italy. Society Volumes: Spain., Biomolecules like proteins and enzymes can target and disrupt cancer cell pathways more specifically and with lower toxicity than traditional treatments. However, their lack of stability and methods for their effective delivery still present unsolved challenges. Silica nanocapsules have been proposed as carriers capable of protecting sensitive loads but their use is limited by their low biodegradability. For this reason, breakable silica structures, able to disassemble when exposed to representative levels of biomolecules readily available in the tumor microenvironment (TME), appear as ideal delivery vectors. In this work, we focus on the optimization of the synthesis parameters governing the breakability of organo-silica nanocapsules containing cleavable disulfide bonds. The objective is to trigger selective release in the presence of glutathione (GSH), a key molecule overexpressed in tumor cells. However, disulfide bonds can also be degraded in the presence of other molecules, which reduces the selectivity of delivery. We have modified the synthesis to obtain a response that leads to silica disassembly only when GSH levels are above a certain threshold, while remaining stable against other reductants, such as those present in standard extracellular culture media. The selection of the proper silica precursor was critical to obtain silica capsules that is able to disassemble and release Cytochrome C (CytC) upon exposure to GSH concentrations typical of those existing in the TME., The authors acknowledge financial support from the Spanish Ministry of Science, Innovation and Universities (FPI Ayuda PRE2022-104024 and Plan Nacional project CONCERT, PID2023-148732NB-I00). Luisa De Cola thanks the European Union´s Horizon 2020 research and innovation programme under grant agreement No 964386, project acronym “MimicKEY”. The synthesis of materials has been performed by the Platform of Production of Biomaterials and Nanoparticles of the NANBIOSIS ICTS, more specifically by the Nanoparticle Synthesis Unit (Unit 9) of the CIBER in BioEngineering, Biomaterials & Nanomedicine (CIBER-BBN). The TEM studies were conducted at the Laboratorio de Microscopias Avanzadas, Instituto de Nanociencia y Materiales de Aragon, Universidad de Zaragoza, Spain. (SAI and ELECMI). Ayuda CEX2023-001286-S financiada por MICIU/AEI /10.13039/501100011033., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2023-001286-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rational design of EV-mimicking nanoparticles with polarity-based recognition potential for advanced nanocarrier development

  • Rosso, Giada
  • Van Veen, Stijn M.A.
  • Sancho‐Albero, María
  • Tamboia, Giulia
  • Empereur-Mot, Charly
  • Perego, Claudio
  • Kuipers, Marije E.
  • Dumontel, Bianca
  • Ajó, Alessandro
  • Nolte-’t Hoen, Esther N.
  • Pavan, Giovanni M.
  • De Cola, Luisa
  • Albertazzi, Lorenzo
  • Cauda, Valentina
Extracellular vesicles (EVs) are natural carriers that are essential for intracellular communication, delivering biomolecules with high efficiency and selectivity. Their application in a clinical setting has been limited, however, due to their complexity and heterogeneity, which hamper standardization in isolation procedures. A solution could be to engineer synthetic nanoparticles that are able to mimic the natural EV structure and function, which would lead to innovative therapeutic nanoplatforms with key advantages over traditional synthetic nanoparticles in terms of toxicity and efficacy. Here, we report an approach to designing, synthesizing, and characterizing lipid-coated nanoparticles engineered to replicate key biophysical surface properties of EVs relevant to cellular recognition and biointerface interactions. Three different lipidic mixtures were designed based on lipidomic data of prostate cancer-derived EVs, taking into consideration the mass percentage of both the lipid families and the fatty acids. Furthermore, breakable organosilica nanocapsules were employed as a functional core and coated with the lipidic mixtures to form eventual EV-mimicking nanocarriers (EV Mimics). Computational modeling of the lipid bilayer was employed to further optimize the lipid coverage of the organosilica nanocapsules. In addition to conventional characterization techniques, which assessed the matching of size and surface charge of EV Mimics and natural EVs, we used advanced single-particle characterization techniques, such as high-resolution flow cytometry and super-resolution microscopy, to assess coating efficacy, size distribution, and lipid polarity─a key parameter in cellular uptake and membrane interaction of EV Mimics. This multidisciplinary approach led to the discovery of a formulation (called “CE Mimic 3”, composed of Chol/SM/PE/PC/PS with respective mass ratios of 30/16.1/12.9/20.9/20.1) that closely reproduces the size, charge, lipid coating, and polarity of natural EVs, thus laying the groundwork for the development of EV-mimetic nanoplatforms for biomedical applications such as targeted delivery or biosensing., This work has received funding from the European Union’s Horizon 2020 Research and Innovation program under Grant Agreement No. 964386─FET Open RIA project acronym “MimicKEY”. M.S.-A. thanks the AIRC Foundation for Cancer Research for a Postdoctoral fellowship in Italy (26907-2021). The Cryo-TEM measurements were conducted by the Platform of Production of Biomaterials and Nanoparticles of the NANBIOSIS ICTS, more specifically by the Nanoparticle Synthesis Unit (UNIT 9) of the CIBER in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN). The CryoEM images were acquired at the Laboratorio de Microscopías Avanzadas, Instituto de Nanociencia y Materiales de Aragon, Universidad de Zaragoza, Spain. (SAI and ICTS ELECMI)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Two Different Responsive Organosilica Nanocarriers to Combine Chemo- and Immunotherapy against Cancer

  • Sancho-Albero, Maria
  • Fenaroli, Alessia Lucrezia
  • Scaccaglia, Mirco
  • Matteo, Cristina
  • Grasselli, Chiara
  • Zucchetti, Massimo
  • Frapolli, Roberta
  • Nastasi, Claudia
  • De Cola, Luisa
The combination of chemo- and immunotherapy was recently demonstrated to improve a patient’s response to therapy, giving rise to an emerging cancer treatment known as chemoimmunotherapy (CIT). Despite the promising benefits of CIT, the most important challenges are (i) the simultaneous or time-controlled delivery of two drugs and (ii) the selective uptake into different cells for each of the drugs: cancer cells for the chemotherapeutic and macrophages for the immunostimulation actives. Herein, a delivery strategy based on morphologically different stimuli-responsive breakable organosilica nanocarriers is exploited to transport two distinct drugs in the different cells using different times of delivery. We employ stimulus-sensitive, PEGylated organosilica nanocages to encapsulate the chemotherapeutic agent doxorubicin, which is preferentially taken up by tumor cells vs macrophages. On the other hand, similar size mesoporous organosilica nanoparticles, preferentially internalized by macrophages, are filled with the immunostimulator resiquimod. The administration in a sequential manner of the two different nanocarriers allowed us to assess the integrated effect of the combined therapy versus treatment with a single drug. In vitro work clearly shows an important reduction of tumor cell viability when both chemo- and immunotherapeutic agents are delivered.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Glutathione Threshold‐Triggered Selective Breakability of Organosilica Nanocapsules

  • Mosseri, Andrea
  • Rueda-Flores, Ana
  • Hueso, Jose L.
  • Urriolabeitia, Esteban
  • De Cola, Luisa
  • Santamaria, Jesus
Biomolecules like proteins and enzymes can target and disrupt cancer cell pathways more specifically and with lower toxicity than traditional treatments. However, their lack of stability and methods for their effective delivery still present unsolved challenges. Silica nanocapsules have been proposed as carriers capable of protecting sensitive loads but their use is limited by their low biodegradability. For this reason, breakable silica structures, able to disassemble when exposed to representative levels of biomolecules readily available in the tumor microenvironment (TME), appear as ideal delivery vectors. In this work, we focus on the optimization of the synthesis parameters governing the breakability of organo‐silica nanocapsules containing cleavable disulfide bonds. The objective is to trigger selective release in the presence of glutathione (GSH), a key molecule overexpressed in tumor cells. However, disulfide bonds can also be degraded in the presence of other molecules, which reduces the selectivity of delivery. We have modified the synthesis to obtain a response that leads to silica disassembly only when GSH levels are above a certain threshold, while remaining stable against other reductants, such as those present in standard extracellular culture media. The selection of the proper silica precursor was critical to obtain silica capsules that is able to disassemble and release Cytochrome C (CytC) upon exposure to GSH concentrations typical of those existing in the TME.